Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

TSX:TRIL - Post Discussion

Trillium Therapeutics Inc. > Orphan Drug Designation
View:
Post by Erudite on Mar 20, 2018 8:42am

Orphan Drug Designation

Wow!  This is great news, finally!  Let's see how the market reacts today.
All fingers and toes crossed.
GLTA
Erudite
Comment by HuntNGather on Mar 20, 2018 11:28am
Oh Erudite... I am with you on that. This is apparently very good news and a solid shot in the arm in support of what the TRIL people are doing.  Safe, Effective... all good words. I too hoped (and still hope) that it will translate into a bump. But alas, it has lived up to the past performance history in the immediate term. Bad news .... fall off a cliff. Good news.... roll down a hill ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities